2. Cancer
  3. Cancer Targeted Therapy

Cancer Targeted Therapy

Cancer targeted therapy is the foundation of precision medicine; it uses drugs or other substances to target specific genes and proteins that control cancer cells’ growth, division and spreading. Compared to traditional chemotherapy drugs, targeted-drugs can specifically act on cancer cells with high efficacy without damaging normal cells. Drugs used in cancer targeted therapy mainly includes small molecules and macromolecules (e.g., monoclonal antibodies), which can target cancer cells and constituents in the tumor microenvironment to activate the immune system. Anti-angiogenesis drugs, such as those targeting vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), transforming growth factor (TGF)-α, TGF-β, Tumor necrosis factor (TNF)-α, and platelet-derived endothelial growth factor (PDGFR) inhibit the proliferation and metastasis of cancer cells. In recent years, the proportion of antibody drugs in cancer treatment has gradually become prominent. Antibody-drug conjugates (ADCs) are a new type of targeted drugs that are composed of monoclonal antibody, cytotoxic drug and linker. ADCs can deliver drugs to tumor cells and minimize the toxicity to normal tissues. Proteolysis-targeting chimera (PROTAC) is a useful technology for targeted protein degradation. PROTAC exploits the ubiquitin-proteasome system and forms a ternary complex with a hijacked E3 ubiquitin ligase and target protein, leading to polyubiquitination and degradation of the target protein.

Targeted therapy is a useful strategy in treatment of cancer either alone or in combination with standard chemotherapy. At present, targeted therapy has proved significant clinical success in the treatment of many types of cancer, including breast cancer, colorectal cancer, leukemia, ovarian cancer and lung cancer.

Productos relacionados con Cancer Targeted Therapy (44277):

Cat. No. Nombre del producto No. CAS Pureza Estructura química
  • HY-W953393
    CRBN ligand-354 2925092-10-8
    CRBN ligand-354 is an E3 ubiquitin ligase cereblon (CRBN) ligand used to recruit the cereblon protein. CRBN ligand-354 can be linked to a target protein ligand via a linker to form a PROTAC.
    CRBN ligand-354
  • HY-W952976
    CRBN ligand-437 2925081-13-4
    CRBN ligand-437 is an E3 ubiquitin ligase cereblon (CRBN) ligand used to recruit the cereblon protein. CRBN ligand-437 can be linked to a target protein ligand via a linker to form a PROTAC.
    CRBN ligand-437
  • HY-109068AR
    Parsaclisib hydrochloride (Standard) 1995889-48-9
    Parsaclisib hydrochloride (Standard) is the analytical standard of Parsaclisib (hydrochloride) (HY-109068A). This product is intended for research and analytical applications. Parsaclisib hydrochloride (INCB050465 hydrochloride) is a potent, selective and orally active inhibitor of PI3Kδ, with an IC50 of 1 nM at 1 mM ATP. Parsaclisib hydrochloride shows approximately 20000-fold selectivity over other PI3K class I isoforms. Parsaclisib hydrochloride can be used for the research of relapsed or refractory B-cell malignancies.
    Parsaclisib hydrochloride (Standard)
  • HY-101029R
    MBM-55 (Standard) 2083622-09-5
    MBM-55 (Standard) is the analytical standard of MBM-55 (HY-101029). This product is intended for research and analytical applications. MBM-55 is a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC50 of 1 nM. MBM-55 shows a 20-fold or greater selectivity in most kinases with the exception of RSK1 (IC50=5.4 nM) and DYRK1a (IC50=6.5 nM). MBM-55 effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-55 shows antitumor activities, and no obvious toxicity to mice.
    MBM-55 (Standard)
  • HY-136570A
    GSK778 hydrochloride 2863657-79-6
    GSK778 (iBET-BD1) hydrochloride is a potent and selective BD1 bromodomain inhibitor of the BET proteins, with IC50s of 75 nM (BRD2 BD1), 41 nM (BRD3 BD1), 41 nM (BRD4 BD1), and 143 nM (BRDT BD1), respectively.
    GSK778 hydrochloride
  • HY-W063558
    tert-Butyl 7-(aminomethyl)-2-azaspiro[3.5]nonane-2-carboxylate 1638767-03-9 ≥98.0%
    tert-Butyl 7-(aminomethyl)-2-azaspiro[3.5]nonane-2-carboxylate is a PROTAC linker that can be used in the synthesis of PROTACs.
    tert-Butyl 7-(aminomethyl)-2-azaspiro[3.5]nonane-2-carboxylate
  • HY-N1939R
    Icariside I (Standard) 56725-99-6
    Icariside I (Standard) is the analytical standard of Icariside I (HY-N1939). This product is intended for research and analytical applications. Icariside I (GH01) is an orally active metabolite of icalin. Icariside I improves estrogen deficiency-induced osteoporosis by simultaneously regulating osteoblast and osteoclast differentiation. Icariside I promotes ATP (HY-B2176) or Nigericin (HY-127019)-induced mtROS production and NLRP3 inflammasome activation and causes idiosyncratic hepatotoxicity. Icariside I does not alter the activation of NLRC4 and AIM2 inflammasomes. Icariside I inhibits breast cancer proliferation, apoptosis, invasion, and metastasis by targeting the IL-6/STAT3 pathway. Icariside I is a kynurenine-AhR pathway inhibitor that alleviates cancer by blocking tumor immune escape.
    Icariside I (Standard)
  • HY-W999721
    CRBN ligand-845
    CRBN ligand-845 is an E3 ubiquitin ligase cereblon (CRBN) ligand used to recruit the cereblon protein. CRBN ligand-845 can be linked to a target protein ligand via a linker to form a PROTAC.
    CRBN ligand-845
  • HY-164484
    IHMT-RAF-128 2479289-15-9
    IHMT-RAF-128, a highly potent pan-RAF inhibitor. IHMT-RAF-128 shows potent antitumor efficacy in xenograft mouse tumor models without causing any apparent toxicities.
    IHMT-RAF-128
  • HY-10530R
    Varlitinib (Standard) 845272-21-1
    Varlitinib (Standard) is the analytical standard of Varlitinib (HY-10530). This product is intended for research and analytical applications. Varlitinib (ASLAN001) is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively.
    Varlitinib (Standard)
  • HY-W002927
    2-(Piperidin-4-yl)-acetic acid ethyl ester 59184-90-6
    2-(Piperidin-4-yl)-acetic acid ethyl ester is a PROTAC linker that can be used in the synthesis of PROTACs.
    2-(Piperidin-4-yl)-acetic acid ethyl ester
  • HY-50751R
    Linifanib (Standard) 796967-16-3
    Linifanib (Standard) is the analytical standard of Linifanib. This product is intended for research and analytical applications. Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib shows prominent antitumor activity. Linifanib has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib is a specific miR-10b inhibitor that blocks miR-10b biogenesis.
    Linifanib (Standard)
  • HY-W154265
    2,2′-Dihydroxychalcone 15131-80-3
    2,2′-Dihydroxychalcone, a flavonoid, is a glutathione S-transferase (GST) inhibitor with an IC50 of 28.9 μM in human colon cancer cells. 2,2′-Dihydroxychalcone induces cell cycle arrest and apoptosis in prostate cancer cells. 2,2′-Dihydroxychalcone has anticancer and anti-inflammatory properties.
    2,2′-Dihydroxychalcone
  • HY-P2044
    Azumamide E 585535-37-1
    Azumamide E is a HDAC inhibitor, with an IC50 of 0.064 μM against HDAC, 1.22 μM against HDAC1, and 2.28 μM against HDAC4. Azumamide E inhibits HDAC activity in nuclear extracts of leukemia cells and cervical adenocarcinoma cells. Azumamide E suppresses angiogenesis. Azumamide E is applicable for research on leukemia, cervical adenocarcinoma, and anti-angiogenesis.
    Azumamide E
  • HY-160635
    Ack1 inhibitor 2 1196392-26-3
    Ack1 inhibitor 2 (Example 259) is an Ack1 inhibitor (IC50: 0.46 μM).
    Ack1 inhibitor 2
  • HY-W999560
    CRBN ligand-889 1049801-63-9
    CRBN ligand-889 is an E3 ubiquitin ligase cereblon (CRBN) ligand used to recruit the cereblon protein. CRBN ligand-889 can be linked to a target protein ligand via a linker to form a PROTAC.
    CRBN ligand-889
  • HY-W953771
    CRBN ligand-250 2925101-82-0
    CRBN ligand-250 is an E3 ubiquitin ligase cereblon (CRBN) ligand used to recruit the cereblon protein. CRBN ligand-250 can be linked to a target protein ligand via a linker to form a PROTAC.
    CRBN ligand-250
  • HY-W952919
    CRBN ligand-380 2925075-98-3
    CRBN ligand-380 is an E3 ubiquitin ligase cereblon (CRBN) ligand used to recruit the cereblon protein. CRBN ligand-380 can be linked to a target protein ligand via a linker to form a PROTAC.
    CRBN ligand-380
  • HY-W077025
    Hydroxy-PEG3-I 136399-06-9
    Hydroxy-PEG3-I is a PROTAC linker that can be used in the synthesis of PROTACs.
    Hydroxy-PEG3-I
  • HY-10410R
    TG101209 (Standard) 936091-14-4
    TG101209 (Standard) is the analytical standard of TG101209 (HY-10410). This product is intended for research and analytical applications. TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM, less potent to Flt3 and RET with IC50 of 25 nM and 17 nM, appr 30-fold selective for JAK2 than JAK3, and sensitive to JAK2V617F and MPLW515L/K mutations.
    TG101209 (Standard)